HEPARIN SODIUM Drug Interactions
Also known as: Heparin Sodium
Heparin Sodium is an anticoagulant medication, often called a blood thinner. It works by helping your body's natural proteins prevent blood clots from forming or growing larger. This medicine is primarily used to prevent and treat serious conditions caused by blood clots, such as deep vein thrombosis (DVT) and pulmonary embolism, and to prevent clotting during certain medical procedures.HEPARIN SODIUM has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Taking naproxen and heparin together significantly increases your risk of bleeding, including serious internal bleeding. This combination should generally be avoided unless specifically directed and closely monitored by your doctor.
Mechanism
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. This leads to impaired platelet aggregation and can cause gastrointestinal mucosal damage, increasing bleeding risk. Heparin is an anticoagulant that directly inhibits clotting factors, further impairing the blood's ability to clot. The combined antiplatelet effect of naproxen and anticoagulant effect of heparin result in an additive and synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can range from minor bruising or nosebleeds to severe, life-threatening hemorrhage, particularly gastrointestinal bleeding. Studies show that concurrent use of NSAIDs with anticoagulants can increase the risk of serious GI bleeding by 3 to 15 times compared to anticoagulants alone. Other potential bleeding sites include intracranial, genitourinary, and surgical sites. This combination should generally be avoided. If concurrent use is absolutely necessary, it must be done under strict medical supervision with frequent monitoring for signs of bleeding (e.g., blood in stool, unusual bruising, dizziness). Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. If an NSAID is required, a COX-2 selective inhibitor might be considered, though it still carries significant risk.
Combining etodolac (an NSAID) with heparin significantly increases your risk of serious bleeding, including internal bleeding. This combination should generally be avoided.
Mechanism
Etodolac inhibits prostaglandin synthesis, which can impair gastric mucosal protection and inhibit platelet aggregation. Heparin directly inhibits clotting factors, leading to systemic anticoagulation. The combined effect significantly amplifies the risk of bleeding by impairing both primary hemostasis (platelet function) and secondary hemostasis (coagulation cascade).
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can range from minor bruising or nosebleeds to severe, life-threatening internal hemorrhages, including gastrointestinal bleeding, intracranial hemorrhage, or retroperitoneal bleeding. The risk of major gastrointestinal bleeding can be 3-15 times higher when NSAIDs are co-administered with anticoagulants. This combination should generally be avoided due to the high risk of serious bleeding. If concurrent use is absolutely necessary, it should be under strict medical supervision with frequent monitoring for signs of bleeding, including complete blood count and coagulation parameters. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. If an NSAID is unavoidable, a COX-2 selective agent might be considered, but still with extreme caution, or a proton pump inhibitor for GI protection.
Combining aspirin with heparin significantly increases your risk of bleeding, including serious internal bleeding. Your healthcare provider will carefully weigh the benefits against this increased risk.
Mechanism
Aspirin inhibits platelet aggregation irreversibly by acetylating cyclooxygenase-1 (COX-1), reducing thromboxane A2 production, which impairs primary hemostasis. Heparin exerts its anticoagulant effect by potentiating antithrombin, leading to inactivation of thrombin and factor Xa. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, severely compromising the body's ability to form clots.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can manifest as gastrointestinal bleeding (e.g., ulcers, melena), intracranial hemorrhage, hematuria, epistaxis, or easy bruising. The risk of major bleeding is significantly elevated, potentially leading to anemia, shock, or death. This combination can increase the risk of serious bleeding by 3 to 15 times compared to either drug alone. Avoid concurrent use if possible. If co-administration is unavoidable, close monitoring for signs and symptoms of bleeding (e.g., blood in stool, unusual bruising, dizziness) is essential. Consider lower doses of one or both agents if clinically appropriate and monitor complete blood count (CBC) regularly. Patient education on bleeding precautions is critical, and immediate medical attention should be sought for any bleeding signs.
Combining ibuprofen with heparin significantly increases your risk of bleeding, including serious internal bleeding. This combination should generally be avoided.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits platelet aggregation and can cause gastrointestinal mucosal damage. Heparin is an anticoagulant that directly inhibits clotting factors, thereby prolonging clotting time. The combined antiplatelet and anticoagulant effects are additive, leading to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can manifest as gastrointestinal bleeding (e.g., ulcers, melena), bruising, epistaxis, hematuria, or more severe internal hemorrhages (e.g., intracranial, retroperitoneal). Studies show a 3-15 fold increased risk of GI bleeding when NSAIDs are co-administered with anticoagulants. This combination should generally be avoided due to the high bleeding risk. If concurrent use is unavoidable, close monitoring for signs of bleeding is essential, and the lowest effective doses for the shortest duration should be used. Consider alternative pain management strategies or alternative anticoagulants if clinically appropriate. Proton pump inhibitors may be co-prescribed to reduce GI bleeding risk.
Combining indomethacin with heparin significantly increases your risk of bleeding, which can be severe. This interaction can lead to internal bleeding, especially in the stomach or intestines.
Mechanism
Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, leading to reduced prostaglandin synthesis. This results in impaired platelet aggregation and direct irritation to the gastrointestinal mucosa. Heparin is an anticoagulant that inhibits the coagulation cascade, reducing the formation of fibrin clots. The additive antiplatelet effect of indomethacin combined with the anticoagulant effect of heparin leads to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding. This includes gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and bleeding from other sites. The risk of serious GI bleeding can be 3-15 times higher when NSAIDs are combined with anticoagulants. This combination should generally be avoided due to the high risk of bleeding. If concurrent use is absolutely necessary, it should be done with extreme caution, close monitoring for signs of bleeding (e.g., black tarry stools, easy bruising, nosebleeds), and potentially with gastroprotective agents (e.g., PPIs). Consider alternative pain management strategies that do not increase bleeding risk, or alternative anti-inflammatory agents if appropriate.
Combining celecoxib with heparin significantly increases your risk of bleeding, which can be serious or even life-threatening. Your doctor will likely avoid this combination or monitor you very closely.
Mechanism
Celecoxib, an NSAID, inhibits prostaglandin synthesis, which can impair platelet function and disrupt the integrity of the gastrointestinal mucosa. Heparin is an anticoagulant that inhibits various clotting factors, primarily through potentiation of antithrombin. The combined effect of impaired platelet aggregation, mucosal damage, and systemic anticoagulation leads to an additive and synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and bleeding from other sites. This risk can be substantial, with GI bleeding risk potentially 3-15 times higher than with either drug alone. Symptoms may include black, tarry stools, blood in vomit, easy bruising, or unusual bleeding. This combination should generally be avoided due to the high risk of serious bleeding. If co-administration is absolutely necessary, the patient must be closely monitored for signs and symptoms of bleeding, and laboratory parameters such as hemoglobin, hematocrit, and coagulation tests (e.g., aPTT) should be regularly assessed. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen.
Combining piroxicam (an NSAID) with heparin (a blood thinner) significantly increases your risk of serious bleeding. This combination should generally be avoided.
Mechanism
Piroxicam inhibits cyclooxygenase (COX-1 and COX-2) enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Heparin directly inhibits clotting factors, preventing clot formation. The concurrent use results in additive antiplatelet and anticoagulant effects, severely compromising the body's ability to form clots and stop bleeding.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other serious bleeding events. The risk of major gastrointestinal bleeding can be several-fold higher compared to either drug alone. This combination should be avoided whenever possible. If an NSAID is absolutely necessary, consider alternative analgesics or non-pharmacological pain management. If concurrent use is unavoidable, closely monitor for signs of bleeding (e.g., black stools, easy bruising, nosebleeds) and consider lower doses of both agents with frequent coagulation monitoring. Proton pump inhibitor prophylaxis may be considered for GI protection.
Combining meloxicam with heparin significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal defense and inhibit platelet aggregation. Heparin is an anticoagulant that directly inhibits various coagulation factors. The combined effect leads to an additive impairment of hemostasis and increased risk of bleeding.
Clinical Management
Patients are at a substantially increased risk of serious bleeding, including gastrointestinal bleeding, intracranial hemorrhage, and other major bleeding events. The risk of gastrointestinal bleeding can be 3 to 15 times higher when NSAIDs are combined with anticoagulants compared to anticoagulants alone. Symptoms may include black, tarry stools, vomiting blood, unusual bruising, or prolonged bleeding from minor cuts. This combination should be avoided whenever possible. If concurrent use is absolutely necessary, it should be done with extreme caution, close monitoring for signs of bleeding, and consideration of gastroprotective agents (e.g., PPIs). Alternative pain management strategies that do not increase bleeding risk should be explored. If bleeding occurs, prompt medical attention is required.
Combining diclofenac with heparin significantly increases your risk of bleeding, particularly in the stomach or intestines. This combination should generally be avoided due to the serious potential for harm.
Mechanism
Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis. This leads to impaired platelet aggregation and can damage the gastrointestinal mucosa. Heparin is an anticoagulant that inhibits various coagulation factors, preventing clot formation. The concurrent use results in additive antiplatelet and anticoagulant effects, severely compromising hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding, including gastrointestinal hemorrhage, intracranial hemorrhage, and other major bleeding events. Patients may experience symptoms like black tarry stools, blood in vomit, easy bruising, or prolonged bleeding from minor cuts. The risk of major gastrointestinal bleeding can be several-fold higher compared to either drug alone. This combination should generally be avoided. If both agents are absolutely necessary, use the lowest effective dose of diclofenac for the shortest possible duration, and consider a gastroprotective agent (e.g., proton pump inhibitor). Closely monitor for signs of bleeding, and regularly assess coagulation parameters (e.g., aPTT for unfractionated heparin). Explore alternative pain management strategies that do not increase bleeding risk.
Combining ketorolac with heparin significantly increases your risk of serious bleeding, including internal bleeding. This combination should generally be avoided.
Mechanism
Ketorolac, an NSAID, inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis. This leads to impaired platelet aggregation and can damage the gastrointestinal mucosa. Heparin directly inhibits clotting factors, preventing clot formation. The concurrent use of both agents results in additive antiplatelet and anticoagulant effects, severely compromising hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding, such as gastrointestinal hemorrhage, intracranial hemorrhage, or other major bleeding events. This risk is dose-dependent and can be life-threatening. Studies indicate that concurrent use of NSAIDs and anticoagulants can increase the risk of GI bleeding by 3 to 15 times compared to anticoagulants alone. This combination should be avoided whenever possible. If both agents are absolutely necessary, extremely close monitoring for signs of bleeding (e.g., melena, hematemesis, petechiae, bruising, altered mental status) is mandatory. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids. If an NSAID is required, a COX-2 selective inhibitor might be considered with extreme caution, but ketorolac is non-selective and carries high risk.
For complete prescribing information:
View full HEPARIN SODIUM monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.